Evidence map›Paper›PMID 22568412›Full record

ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2012

Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy.

Ching-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, Xuemei Wang, Peter W T Pisters, Jean-Nicolas Vauthey, Gauri Varadhachary, Robert A Wolff, Matthew H G Katz

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04622423 (Advanced Immune Gene and Cell Therapies for Liver Metastases), which is not on this map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04622423 recruitingnot on this mapstarted 2019, after this paper: background citation

Advanced Immune Gene and Cell Therapies for Liver Metastases

TypeobservationalSponsorIRCCS San RaffaeleRan2019 to 2030Enrolled625ConditionsPancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jason B Fleming
Jeffrey E Lee
Xuemei Wang
Peter W T Pisters
Jean-Nicolas Vauthey
Gauri Varadhachary
Robert A Wolff
Matthew H G Katz

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundFollowing potentially curative resection at this centre, patients with pancreatic adenocarcinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study sought to evaluate its diagnostic yield.

methodsAll patients who underwent pancreaticoduodenectomy for PAC at this institution during 1998-2008 were identified. Patients with asymptomatic recurrence were compared with those with symptomatic recurrence. Factors associated with survival following the detection of recurrence were compared.

resultsA total of 216 of 327 (66.1%) resected patients developed recurrence. Asymptomatic recurrence was detected in 118 (54.6%) patients. Symptomatic recurrence was associated with multifocal disease or carcinomatosis, poor performance status and less frequent subsequent therapy. Median time to recurrence did not differ between groups, but survival after detection was shorter in symptomatic patients (5.1 months vs. 13.0 months; P < 0.001). Treatment was administered more frequently to asymptomatic patients (91.2% vs. 61.4%; P < 0.001). At recurrence, a preserved performance status score of ≤ 1, further therapy, low CA 19-9, and an isolated site of recurrence were independently associated with longer post-recurrence survival (P < 0.001).

conclusionsOverall, 54.6% of cases of recurrent PAC were detected prior to the onset of symptoms using a standardized clinical and radiographic surveillance strategy. Although this retrospective analysis limits definitive conclusions associating this strategy with survival, these results suggest the need for further studies of postoperative surveillance.

Indexed as

Multidetector Computed TomographyPancreaticoduodenectomyAdenocarcinomaAsymptomatic DiseasesChemotherapy, AdjuvantChi-Square DistributionContrast MediaDisease-Free SurvivalHumansKaplan-Meier EstimateMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalPancreatic NeoplasmsPredictive Value of TestsProportional Hazards ModelsContrast Media

Identifiers

PMID22568412
PMCPMC3384860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.